MiRNA Scientific
MiRNA Scientific is a precision molecular diagnostics company developing non-invasive liquid biopsy urine tests for cancer detection. Its flagship miR Sentinel Prostate Cancer Test analyzes small non-coding RNA from urinary exosomes to classify prostate cancer risk for healthcare providers and patients.
- Company typePrivate
- Founded2024
- HeadquartersNorth Brunswick, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What MiRNA Scientific does
MiRNA Scientific is a precision molecular diagnostics company headquartered at 685 Route 1 South, Suite 110 in North Brunswick, New Jersey, with operating subsidiaries in Israel. The firmographic founding year is 2024, though company-history events (including the July 2018 appointment of Chief Medical Officer Laurence Klotz, M.D., FRCSC) indicate that substantive operating activity dates back to at least 2018, suggesting the 2024 date may reflect a reincorporation or entity restructuring. The company is a majority-owned subsidiary of Huminn LLC (formerly Impact NRS), a holding/investment parent. Headcount is 11-50 employees, and the company has no public listing.
The company's core technology is the proprietary miR Disease Management Platform®, which isolates and interrogates small non-coding RNA (sncRNA) extracted from urinary exosomes on a high-throughput OpenArray system and applies a proprietary scoring algorithm to produce molecular risk classifications. Its flagship commercial product is the miR Sentinel™ Prostate Cancer Test — described as the first non-invasive liquid biopsy urine test to detect, classify, and monitor prostate cancer at the molecular level without reliance on PSA, DRE, or biopsy tissue. The test stratifies patients into three categories: No Molecular Evidence of Prostate Cancer (NMEPC), Low Risk for Aggressive Prostate Cancer, or Elevated Risk for Aggressive Prostate Cancer. The platform is positioned to extend beyond prostate cancer to other urological cancers including bladder and kidney, although those indications have not yet been commercialized. Clinical validation was published in the Journal of Urology in August 2020, FDA Breakthrough Device Designation was received in October 2020, and CAP Accreditation of the CLIA laboratory followed in October 2023.
MiRNA Scientific generates revenue via a per-test diagnostic service model: healthcare providers (primarily urologists and primary care physicians) order the test, patients provide a single urine specimen, and the company analyzes samples at its CLIA-certified laboratory. Revenue is recorded as one-time per test. Pricing is not publicly disclosed. The company serves four explicit customer segments — providers, patients, self-insured employers, and payors/insurers — with distribution focused on the United States and expanding internationally via channel partnerships, specifically Singapore (Leonie Hill Capital, March 2022) and Puerto Rico (government cooperation agreement, November 2020). The company operates a direct enterprise field sales motion targeting healthcare providers for clinical adoption.
MiRNA Scientific firmographics
Firmographics- Name
- MiRNA Scientific
- Legal name
- MiRNA Scientific, LLC
- Website
- https://mirnascientific.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MiRNA Scientific is a precision molecular diagnostics company developing non-invasive liquid biopsy urine tests for cancer detection. Its flagship miR Sentinel Prostate Cancer Test analyzes small non-coding RNA from urinary exosomes to classify prostate cancer risk for healthcare providers and patients.
- Ownership category
- akta.pro rank
MiRNA Scientific industry classification
Industry- Product category
- Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where MiRNA Scientific is headquartered
LocationHeadquarters
- HQ city
- North Brunswick
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MiRNA Scientific business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- miR Sentinel Prostate Cancer Test: Revenue generated from providing molecular diagnostic testing services for prostate cancer detection and classification. Healthcare providers order the test, patients provide urine samples, and the company analyzes samples in its CLIA-certified laboratory to deliver molecular risk assessments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
MiRNA Scientific product offering
Product offeringCore offering
MiRNA Scientific provides molecular diagnostic laboratory services for cancer detection and classification, with its flagship miR Sentinel™ Prostate Cancer Test analyzing small non-coding RNA (sncRNA) extracted from a single urine specimen. The test categorizes patients into No Molecular Evidence of Prostate Cancer (NMEPC), Low Risk for Aggressive Prostate Cancer, or Elevated Risk for Aggressive Prostate Cancer, and runs on the proprietary miR Disease Management Platform® at the company's CLIA-certified, CAP-accredited laboratory.
Product overview
MiRNA Scientific offers a platform-plus-products architecture centered on its proprietary miR Disease Management Platform®, which delivers molecular diagnostic tests for cancer detection and classification. The primary commercial product is the miR Sentinel™ Prostate Cancer Test, the first and only non-invasive liquid biopsy urine test that detects, classifies, and monitors prostate cancer at the molecular level using sncRNA analysis. The platform initially focuses on urological cancers (prostate, bladder, and kidney) and uses advanced sncRNA interrogation techniques combined with a proprietary scoring algorithm to provide risk stratification from a single urine sample.
Differentiator
Problem solved
Functional benefit
Brands
- miR Sentinel: The company's flagship product brand for its prostate cancer liquid biopsy test. miR Sentinel is a non-invasive urine test that detects, classifies and monitors prostate cancer at the molecular level.
- miR Disease Management Platform
Products and services
- miR Sentinel™ Prostate Cancer Test Non-invasive liquid biopsy urine test that detects, classifies, and monitors prostate cancer at the molecular level by analyzing small non-coding RNA (sncRNA) extracted from urinary exosomes. Categorizes patients into No Molecular Evidence of Prostate Cancer (NMEPC), Low Risk for Aggressive Prostate Cancer, or Elevated Risk for Aggressive Prostate Cancer. Marketed to healthcare providers (urologists, primary care physicians) and the patients they serve as a non-invasive alternative to PSA, DRE, and core needle biopsy.
Quantifiable outcome
- Current standard of care (PSA + biopsy) has only 44% sensitivity
- +3 more outcomes
Companies that use MiRNA Scientific
Customer profileSegments4 records
Ideal customer profiles2 records
MiRNA Scientific technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
MiRNA Scientific partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and major.
- Leonie Hill CapitalcoreStrategic collaboration to introduce the breakthrough urine liquid biopsy prostate cancer test in Singapore. Leonie Hill Capital serves as the distribution partner for the Singapore market, enabling commercial availability and market access in this international market.
- Puerto Rico GovernmentmajorPioneering cooperation agreement to evaluate impact and deployment of the prostate cancer liquid biopsy test in Puerto Rico. The collaboration includes government support for Prostate Cancer Prevention Day initiatives and represents a significant public health partnership for test deployment in a defined geographic region.
- Huminn LLCcoreMiRNA Scientific is a majority-owned operating subsidiary of Huminn LLC (formerly known as Impact NRS). This is a parent-subsidiary relationship where Huminn LLC owns the majority stake in MiRNA Scientific and provides corporate governance and strategic direction.
Scale indicators6 records
Recent moves6 records
Expansion highlights7 records
MiRNA Scientific competitors and assessment
Company assessmentBroad incumbents
- Hologic: Hologic is a large established diagnostics company with a molecular diagnostics franchise (e.g., Panther system, ThinPrep); relevant as a reference commercial-scale diagnostics operator and channel partner candidate for clinical laboratories.
- Veracyte: Veracyte is a molecular diagnostics company focused on urologic and thyroid cancers (Decipher Prostate, Afirma), directly adjacent to MiRNA's prostate cancer focus and illustrative of the commercial and reimbursement model for specialty urology molecular tests.
- Natera: Natera operates a cell-free DNA and molecular diagnostics platform with applications in oncology, women's health, and organ health; the Signatera MRD test is the closest commercial analog for a high-throughput, lab-developed molecular oncology test.
- Exact Sciences (Cologuard, Oncotype): Exact Sciences is an established molecular diagnostics leader with Cologuard and an oncology portfolio; comparable as a publicly-traded reference point for commercial-stage cancer diagnostics, though its core franchise is colorectal rather than prostate cancer.
- Guardant Health: Guardant Health is a leading liquid biopsy company in oncology, offering blood-based cfDNA tests for cancer detection and monitoring; comparable as a broader liquid biopsy commercial platform targeting similar oncology providers and payors.
Emerging players
- Philogen: Philogen is a clinical-stage biotech with a pipeline that includes urological and other cancer targets; partial overlap as a smaller oncology company with proprietary biological platforms rather than a direct commercial competitor.
- GRAIL: GRAIL is developing Galleri, a multi-cancer early detection liquid biopsy test using methylation-based cfDNA analysis; comparable as an emerging liquid biopsy company targeting large cancer screening populations, though with a different analyte and indication breadth.
Direct peers
- MDxHealth: MDxHealth commercializes the SelectMDx urine-based molecular test for prostate cancer risk stratification, directly competing with miR Sentinel in the same indication, customer base (urologists), and CLIA-lab laboratory-developed test model.
- Exosome Diagnostics (Bio-Techne): Exosome Diagnostics, now part of Bio-Techne, offers the ExoDx Prostate IntelliScore urine-based exosome RNA test for prostate cancer, the closest analog to MiRNA's exosome-sncRNA liquid biopsy approach.
- OPKO Health (4Kscore): OPKO Health markets the 4Kscore blood-based test that helps determine the risk of aggressive prostate cancer, directly competing for the same urology ordering decision and payor dollar as miR Sentinel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MiRNA Scientific social profiles
Digital presenceMiRNA Scientific compliance and trust
Trust signalCompliance4 records
MiRNA Scientific financial estimates
Financial estimateRevenue estimate
Valuation estimate
MiRNA Scientific leadership team
Management profileNumber of profiles
Profiles4 records
MiRNA Scientific subsidiaries and ownership
Company hierarchySubsidiaries1 record
MiRNA Scientific funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MiRNA Scientific M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MiRNA Scientific
What does MiRNA Scientific do?
MiRNA Scientific provides molecular diagnostic laboratory services for cancer detection and classification, with its flagship miR Sentinel™ Prostate Cancer Test analyzing small non-coding RNA (sncRNA) extracted from a single urine specimen. The test categorizes patients into No Molecular Evidence of Prostate Cancer (NMEPC), Low Risk for Aggressive Prostate Cancer, or Elevated Risk for Aggressive Prostate Cancer, and runs on the proprietary miR Disease Management Platform® at the company's CLIA-certified, CAP-accredited laboratory.
Is MiRNA Scientific a public or private company?
MiRNA Scientific is a private company. It is classified as corporate owned and is currently operating.
When was MiRNA Scientific founded?
MiRNA Scientific was founded in 2024. It employs 11 to 50 people.
Where is MiRNA Scientific based?
MiRNA Scientific is headquartered in North Brunswick, United States, in the North America region.
How does MiRNA Scientific make money?
One revenue line is on record: miR Sentinel Prostate Cancer Test.
Who are MiRNA Scientific's main competitors?
Broad incumbents on record are Hologic, Veracyte, Natera, Exact Sciences (Cologuard, Oncotype) and Guardant Health. Emerging players are Philogen and GRAIL. Direct peers are MDxHealth, Exosome Diagnostics (Bio-Techne) and OPKO Health (4Kscore).
Does MiRNA Scientific have an API?
No public API is recorded for MiRNA Scientific.
What industry is MiRNA Scientific in?
MiRNA Scientific's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 621511 and its SIC code is 2835.